SUPPLEMENTARY FINANCIAL INFORMATION (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Less:
Total revenues	$ 225,508	$ 143,096
Gross profit	102,590	59,234
Net loss	$ (10,408)	$ (6,333)
Net loss per common share:
Basic (in Dollars per share)	$ (0.15)	$ (0.09)
Diluted (in Dollars per share)	$ (0.15)	$ (0.09)
Weighted-average common shares outstanding:
Basic (in Shares)	70,665,394	68,967,875
Diluted (in Shares)	70,665,394	68,967,875
Impax Generics
Revenue:
Impax sales, gross	$ 611,281	$ 355,321
Less:
Product Returns	11,913	6,427
Impax product sales, net	167,184	125,959
Total revenues	170,079	128,741
Impax Specialty Pharma
Revenue:
Impax sales, gross	82,073	29,219
Less:
Product Returns	1,508	2,620
Impax product sales, net	55,429	14,128
Total revenues	55,429	14,355
Rx Partner | Impax Generics
Less:
Other Revenues	2,835	2,239
Other Revenues | Impax Generics
Less:
Other Revenues	60	543
Other Revenues | Impax Specialty Pharma
Less:
Other Revenues	0	227
Chargeback Reserve
Less:
Sales Allowances	223,465		$ 833,157
Chargeback Reserve | Impax Generics
Less:
Sales Allowances	217,354	126,607
Chargeback Reserve | Impax Specialty Pharma
Less:
Sales Allowances	6,111	5,561
Rebate Reserve
Less:
Sales Allowances	185,476		$ 571,642
Rebate Reserve | Impax Generics
Less:
Sales Allowances	185,476	83,130
Rebate Reserve | Impax Specialty Pharma
Less:
Sales Allowances	2,853	2,132
Other Credits | Impax Generics
Less:
Sales Allowances	29,354	13,198
Other Credits | Impax Specialty Pharma
Less:
Sales Allowances	$ 16,172	$ 4,778